221
222
223
224
225
226
227
228
229
230
Selvarajah, A., Tavenier, A. H., Bor, W. L., Houben, J.E.M., Rasoul, S., Kaplan, E., Teeuwen, K., Hofma, S. H., Lipsic, E., Amoroso, G., van Leeuwen, M. A. H., ten Berg, J. M., van 't Hof, A. W. J., Hermanides, R. S.
Veröffentlicht in: Selvarajah , A , Tavenier , A H , Bor , W L , Houben , J E M , Rasoul , S , Kaplan , E , Teeuwen , K , Hofma , S H , Lipsic , E , Amoroso , G , van Leeuwen , M A H , ten Berg , J M , van 't Hof , A W J & Hermanides , R S 2021 , ' Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention : rationale of the Dutch Cangrelor Registry ' , BMC Cardiovascular Disorders , vol. 21 , no. 1 , 292 . https://doi.org/10.1186/s12872-021-02093-4;
2021
Veröffentlicht in: Selvarajah , A , Tavenier , A H , Bor , W L , Houben , J E M , Rasoul , S , Kaplan , E , Teeuwen , K , Hofma , S H , Lipsic , E , Amoroso , G , van Leeuwen , M A H , ten Berg , J M , van 't Hof , A W J & Hermanides , R S 2021 , ' Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention : rationale of the Dutch Cangrelor Registry ' , BMC Cardiovascular Disorders , vol. 21 , no. 1 , 292 . https://doi.org/10.1186/s12872-021-02093-4;
2021